VBIV - VBIワクチン (VBI Vaccines Inc.)

VBIVのニュース

   VBI Vaccines wins European recommendation for Hep B vaccine  2022/02/25 14:26:19 Seeking Alpha
VBI Vaccines (VBIV) is trading ~3% higher in the premarket Friday after the commercial stage vaccine maker announced that an expert panel of the European Medicines Agency ((EMA)) issued…
   VBIV stock gains after CDC nod for Hep B vaccine (NASDAQ:VBIV)  2022/02/23 21:22:10 Seeking Alpha
Cambridge, Massachusetts-based vaccine maker VBI Vaccines (VBIV) announced on Wednesday that an expert panel of the U.S
   VBI Vaccines Inc. (NASDAQ: VBIV)’s Stock Is Down -60.98% Since The Beginning Of The Year, Likely To Sustain The Trend In 2022  2022/02/18 15:30:00 Marketing Sentinel
During the last session, VBI Vaccines Inc. (NASDAQ:VBIV)’s traded shares were 1.85 million, with the beta value of the company hitting 1.91. At the end of the trading day, the stock’s price was $1.44, reflecting an intraday loss of -5.88% or -$0.09. The 52-week high for the VBIV share is $4.31, that puts it down … VBI Vaccines Inc. (NASDAQ: VBIV)’s Stock Is Down -60.98% Since The Beginning Of The Year, Likely To Sustain The Trend In 2022 Read More »
   VBI Vaccines Inc. Shares Close in on 52-Week Low - Market Mover  2022/01/09 04:34:29 Kwhen Finance
VBI Vaccines Inc. (VBIV) shares closed today at 1.4% above its 52 week low of $2.09, giving the company a market cap of $545M. The stock is currently down 9.4% year-to-date, down 34.2% over the past 12 months, and down 37.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 31.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -24.7% The company's stock price performance over the past 12 months beats the peer average by -15.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   At 12.6% CAGR, Global Vaccines Market Size to Hit USD 153.49 Bn in 2028, Says Brandessence Market Research  2022/01/03 11:10:00 Kwhen Finance
   Why Shares of VBI Vaccines Soared, and Then Fell 7%, on Tuesday  2021/06/29 20:14:01 The Motley Fool
Investors almost seemed ready to take profits once shares hit their highest level since February.
   Conference data for June 23, 2021: EASL  2021/06/29 19:45:00 BioWorld
Data presented at The International Liver Congress The Annual Meeting of the European Association for the Study of the Liver, including: Brii Biosciences, VBI Vaccines.
   VBI Vaccines Announces Positive Phase 1 Data For EVLP Vaccine Candidate Against COVID-19; Stock Up  2021/06/29 12:15:34 Business Insider Markets
(RTTNews) - VBI Vaccines Inc. (VBIV) announced positive Phase 1 data from its Phase 1/2 trial of the first of its enveloped virus-like particle or eVLP COVID-19 vaccine candidates, VBI-2902a, in healthy adults age 18-54 years of age. In Tuesday pre-market trade, VBIV was trading at $4.33 up $0.32 or 7.98%. The company noted that the 5µg dose
   VBI Vaccines shares rise on data from early-stage COVID-19 vaccine study  2021/06/29 11:58:56 Seeking Alpha
   Samenvatting: Brii Biosciences en VBI-vaccins presenteren positieve gegevens van voltooide fase 1b/2a-studie over BRII-179 (VBI-2601) bij patiënten met chronische hepatitis B op het International Liver Congress 2021  2021/06/23 16:27:00 Business Wire
DURHAM, N.C. & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Brii Biosciences (Brii Bio) en VBI Vaccines Inc. (NASDAQ: VBIV) (VBI), kondigden vandaag de definitieve resultaten aan van een Fase 1b/2a studie met BRII-179 (VBI-2601), een nieuwe recombinante immunotherapeutische kandidaat op basis van eiwitten, bij patiënten met chronische hepatitis B-virus (HBV) infectie. De gegevens van de studie, die de veiligheid, antivirale activiteit en immunogeniciteit van BRII-179 (VBI-2601) alleen of ge
   Why Shares of VBI Vaccines Soared, and Then Fell 7%, on Tuesday  2021/06/29 20:14:01 The Motley Fool
Investors almost seemed ready to take profits once shares hit their highest level since February.
   Conference data for June 23, 2021: EASL  2021/06/29 19:45:00 BioWorld
Data presented at The International Liver Congress The Annual Meeting of the European Association for the Study of the Liver, including: Brii Biosciences, VBI Vaccines.
   VBI Vaccines Announces Positive Phase 1 Data For EVLP Vaccine Candidate Against COVID-19; Stock Up  2021/06/29 12:15:34 Business Insider Markets
(RTTNews) - VBI Vaccines Inc. (VBIV) announced positive Phase 1 data from its Phase 1/2 trial of the first of its enveloped virus-like particle or eVLP COVID-19 vaccine candidates, VBI-2902a, in healthy adults age 18-54 years of age. In Tuesday pre-market trade, VBIV was trading at $4.33 up $0.32 or 7.98%. The company noted that the 5µg dose
   VBI Vaccines shares rise on data from early-stage COVID-19 vaccine study  2021/06/29 11:58:56 Seeking Alpha
   Samenvatting: Brii Biosciences en VBI-vaccins presenteren positieve gegevens van voltooide fase 1b/2a-studie over BRII-179 (VBI-2601) bij patiënten met chronische hepatitis B op het International Liver Congress 2021  2021/06/23 16:27:00 Business Wire
DURHAM, N.C. & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Brii Biosciences (Brii Bio) en VBI Vaccines Inc. (NASDAQ: VBIV) (VBI), kondigden vandaag de definitieve resultaten aan van een Fase 1b/2a studie met BRII-179 (VBI-2601), een nieuwe recombinante immunotherapeutische kandidaat op basis van eiwitten, bij patiënten met chronische hepatitis B-virus (HBV) infectie. De gegevens van de studie, die de veiligheid, antivirale activiteit en immunogeniciteit van BRII-179 (VBI-2601) alleen of ge

calendar